F-star: F-star Partners Second Early-Stage Tetravalent Bispecific Antibody with Takeda

F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-oncology bispecific antibody to Japan's Takeda. F-star uses its Fcab and mAb2 platforms to discover bispecific candidates. The two companies announced a similar deal for another candidate in 2022. Two weeks ago, Sino Biopharma closed its $161 million acquisition of F-star after the deal was held up by US legislators for nine months. F-star became part of Sino Biopharm's London subsidiary invoX, which conducts Sino Biopharm's ex-China R&D and business development. More details....Share this with colleagues: